Loading...
XASX
CYC
Market cap70mUSD
Dec 05, Last price  
0.95AUD
1D
2.15%
1Q
9.20%
Jan 2017
5.34%
IPO
-56.02%
Name

Cyclopharm Ltd

Chart & Performance

D1W1MN
XASX:CYC chart
P/E
P/S
3.83
EPS
Div Yield, %
Shrs. gr., 5y
8.60%
Rev. gr., 5y
14.39%
Revenues
28m
+1.60%
11,128,22410,888,26913,112,4209,464,60510,314,50610,743,82411,882,13412,046,79712,582,51914,385,50713,188,75213,404,22214,078,80114,676,15717,704,57423,218,79727,139,56127,572,581
Net income
-13m
L+180.75%
1,131,2391,757,0622,044,490450,106-956,220-1,044,127-779,9544,065,5634,793,047891,368-1,524,571-35,456-2,912,440-6,043,636-5,040,166-6,611,515-4,700,806-13,197,618
CFO
-13m
L+74.70%
146,0991,486,0290-90,960563,627369,285706,7064,468,7804,154,834654,794-682,121-1,107,335-489,340-8,934,868-1,629,410-6,664,485-7,197,632-12,574,405
Dividend
Sep 01, 20230.005 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
IPO date
Jan 18, 2007
Employees
63
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT